Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.

The Oncologist
Jorg DietrichTracy T Batchelor

Abstract

The findings from this study using monotherapy with pemetrexed in a pretreated patient population are, overall, encouraging. Unlike high-dose methotrexate, which requires several days of inpatient hospitalization, pemetrexed is relatively easy to administer in the outpatient setting and remains a viable treatment option in this patient population. The maximum tolerated dose of pemetrexed administered (900 mg/m2 every 2 weeks) was generally well tolerated and showed activity in patients with relapsed or refractory CNSL. There is currently no standard salvage treatment for patients with relapsed/refractory central nervous system (CNS) lymphoma (CNSL). We report the results of a phase I study of pemetrexed, an antifolate drug with broader activity than methotrexate (MTX). We provide the safety, tolerability, and maximum tolerated dose (MTD) of pemetrexed in patients with recurrent CNSL. Through October 2015, 17 patients with relapsed/refractory CNSL received pemetrexed every 2 weeks with the first cohort receiving 600 mg/m2 and dose escalation in increments of 300 mg/m2 to a maximum of 1,200 mg/m2 . Three patients were to enroll at each dose level with expansion to six patients in the event of dose-limiting toxicity. Patients with...Continue Reading

References

Sep 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott R PlotkinTracy T Batchelor
Jul 1, 2005·The Journal of Pharmacology and Experimental Therapeutics·Haiqing DaiWilliam F Elmquist
Jan 5, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alain C MitaChris H Takimoto
Apr 11, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L FischerA Korfel
Jul 21, 2006·Cancer Chemotherapy and Pharmacology·Stacie L StapletonSusan M Blaney
Feb 28, 2007·British Journal of Cancer·M ReniA J M Ferreri
Sep 27, 2007·Journal of Neuro-oncology·Alfredo D VoloschinTracy Batchelor
Oct 12, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N B KhimaniP M Mauch
Mar 9, 2011·Neurology·T T BatchelorG J Lesser
Aug 19, 2011·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Ilya G GlezermanSurya V Seshan
Sep 22, 2012·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·S F WongL Cher
Jul 6, 2013·Journal of Neuro-oncology·Jun-Ping ZhangJan Drappatz
Dec 21, 2014·Neurology·Caroline HouillierKhê Hoang-Xuan
Jul 15, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·S HanJ Yu
May 30, 2017·Cancer Cell·Michail S LionakisWyndham H Wilson
Aug 25, 2018·The European Respiratory Journal·Sabine VisserJoachim G J V Aerts

❮ Previous
Next ❯

Citations

Nov 6, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Matthias HoldhoffLakshmi Nayak
Aug 28, 2021·British Journal of Haematology·Nicolas Martinez-CalleElisabeth Schorb
Oct 16, 2021·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Zhenying ChenWeibing Miao

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.